Hakan Goker
Direttore/Membro del Consiglio presso Asceneuron SA
Profilo
Hakan Goker is currently a Director at Asceneuron SA, Forendo Pharma Oy, STORM Therapeutics Ltd., Macrophage Pharma Ltd., iOnctura SA, Ribometrix, Inc., Outrun Therapeutics Ltd., and Vice President at Merck Ventures BV.
He has also held positions as a Director at Orphazyme A, TocopheRx, Inc., SynAffix BV, Raze Therapeutics, Inc., Progyny, Inc., Artios Pharma Ltd., Associate at Atlas Venture LLP, and Partner at Aescap Venture Management BV.
Dr. Goker obtained a doctorate degree from the University of London and an undergraduate degree from University College London.
Posizioni attive di Hakan Goker
Società | Posizione | Inizio |
---|---|---|
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Direttore/Membro del Consiglio | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Direttore/Membro del Consiglio | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investitore di Private Equity | 01/11/2013 |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Direttore/Membro del Consiglio | - |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Direttore/Membro del Consiglio | 01/07/2017 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | Direttore/Membro del Consiglio | 01/04/2021 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Hakan Goker
Società | Posizione | Fine |
---|---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investitore di Private Equity | 01/03/2013 |
░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
Formazione di Hakan Goker
University of London | Doctorate Degree |
University College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ORPHAZYME A/S | Health Technology |
PROGYNY, INC. | Commercial Services |
Aziende private | 14 |
---|---|
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | Finance |
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Health Technology |
TocopheRx, Inc.
TocopheRx, Inc. Medical SpecialtiesHealth Technology TocopheRx, Inc. developed novel therapies for treatment of infertility. The company was founded by Stephen Palmer, Selva Nataraja, and Henry Yu on December 2, 2013 and was headquartered in Gorton, MA. | Health Technology |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
Raze Therapeutics, Inc.
Raze Therapeutics, Inc. BiotechnologyHealth Technology Raze Therapeutics, Inc. engages in the discovery and development of oncology therapeutics. It offers a pipeline of one-carbon (1C) metabolism therapeutics across solid and hematologic cancers, including genetically-defined cancers. The company was founded by Vamsi Mootha, Joshua Rabinowitz, David Sabatini, and Adam Friedman on August 8, 2014 and is headquartered in Cambridge, MA. | Health Technology |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Health Technology |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Commercial Services |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | Health Technology |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | Commercial Services |
- Borsa valori
- Insiders
- Hakan Goker